UCL Technology Fund

UCL Technology Fund is a specialist venture fund dedicated to commercializing research from University College London, operating out of London and focused on the life and physical sciences. The fund is structured as a partnership between UCL Business and AlbionVC, which gives it a hybrid identity combining university tech transfer access with professional venture capital execution.

The thesis is concentrated on biotech, pharma and therapeutics, AI and machine learning applied to healthcare, and life sciences tools. UCL Technology Fund invests where the underlying science emerges from UCL laboratories or affiliated institutions and where the team has the scientific and commercial credibility to execute a clinical or commercial development plan. The healthcare slice spans novel therapeutic modalities, computational drug discovery platforms, and the picks-and-shovels tooling that supports modern life science research.

The fund writes $1M to $5M checks across Pre-Seed, Seed, and Series A. That positioning lets it lead the formation round and continue through the first institutional Series A, with follow-on capacity that supports a meaningful ownership position over multiple rounds. Geographic focus is the United Kingdom and primarily the UCL ecosystem in London, though portfolio companies routinely attract international syndicates as they progress through clinical milestones.

The team operates under the AlbionVC umbrella alongside UCL Business, which provides specialist scientific diligence, IP expertise, and the operational venture experience that AlbionVC’s broader life sciences franchise has developed. Specific partner names are not specified in the source data, and founders should engage through UCLTF’s website and expect to be routed to the partner whose expertise aligns with the underlying science.

The approach combines university tech transfer patience with commercial venture discipline. UCL Technology Fund is comfortable with long timelines and complex IP arrangements but expects credible commercial execution as companies mature past formation. The fund is a strong fit for UCL-affiliated life sciences founders who want a knowledgeable lead investor from incorporation through Series A. Founders without a UCL connection or those operating outside the life and physical sciences will be a poor structural fit and should look to other UK deep tech investors.